China Cord Blood Corp  

(Public, NYSE:CO)   Watch this stock  
Find more results for CO
+0.06 (0.95%)
Nov 27 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 6.33 - 6.42
52 week 4.10 - 7.69
Open 6.33
Vol / Avg. 7,136.00/124,542.00
Mkt cap 506.03M
P/E 35.86
Div/yield     -
EPS 0.18
Shares 80.08M
Beta 0.55
Inst. own 22%
Feb 23, 2016
Q3 2016 China Cord Blood Corp Earnings Release (Estimated) Add to calendar
Nov 24, 2015
Q2 2016 China Cord Blood Corp Earnings Call - Webcast
Nov 23, 2015
Q2 2016 China Cord Blood Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin 8.16% 16.97%
Operating margin 29.29% 37.00%
EBITD margin - 44.97%
Return on average assets 1.29% 2.78%
Return on average equity 3.49% 6.67%
Employees 1,039 -
CDP Score - -


48th Floor, Bank of China Tower 1 Garden Road, Central
Hong Kong
+85236058180 (Phone)
+85236058181 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


China Cord Blood Corporation is principally engaged in the provision of umbilical cord blood storage and ancillary services in the People's Republic of China. The Company provides cord blood testing, processing and storage services under the direction of subscribers. The Company also preserves cord blood units donated by the public, provides matching services on such donated units and delivers matching units to patients in need of transplants. The Company's cord blood banking operations primarily consist of its subscription services, which involve the preservation of cord blood for expectant parents as a precautionary healthcare measure for the benefit of their children and other family members. Its subscription services consist of the collection of the newborn's cord blood unit at one of its collaborating hospitals and the transportation of the cord blood unit to one of its facilities for testing and processing and the long-term storage of the cord blood unit at the facility.

Officers and directors

Yuen Kam Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Ting Zheng Chief Executive Officer, Director
Age: 43
Bio & Compensation  - Reuters
Albert Chen Chief Financial Officer, Director
Age: 39
Bio & Compensation  - Reuters
Rui Arashiyama Chief Executive Officer - Guangdong and Zhejiang Divisions
Age: 56
Bio & Compensation  - Reuters
Yue Deng Chief Executive Officer - Beijing Division
Age: 45
Bio & Compensation  - Reuters
Xin Xu Chief Technology Officer
Age: 61
Bio & Compensation  - Reuters
Mark D. Chen Independent Non-Executive Director
Age: 47
Bio & Compensation  - Reuters
Ken Lu Independent Non-Executive Director
Age: 51
Bio & Compensation  - Reuters
Jennifer J. Weng Independent Non-Executive Director
Age: 47
Bio & Compensation  - Reuters